 |
인쇄하기
취소
|
Genesoft and Genome Therapeutics announce definite merger agreement
Genome Therapeutics (Nasdaq: GENE) and Genesoft Pharmaceuticals Inc. entered into a definite agreement to merge in all-stock transaction on November 18 (ET).
This merger agreement has been approved by the Board of Director at both Genome Therapeutics and Genesoft Pharmaceuticals. Genome Therapeutics will issue $28 million shares of Genome Therapeutics common stock to the existing holders of ...
This merger agreement has been approved by the Board of Director at both Genome Therapeutics and Genesoft Pharmaceuticals. Genome Therapeutics will issue $28 million shares of Genome Therapeutics common stock to the existing holders of ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.